GLOBOCAN 2008, International Agency for Research on Cancer.
2.
SylvesterR.J., van der MeijdenA.P., OosterlinckW., WitjesJ.A., BouffiouxC., DenisL., NewlingD.V., KurthK.Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials.European Urology2006; 49: 466–5.
3.
Santos CortesJ.A., GahanJ., SolowayM.S.Photodynamic diagnosis in urology: state of the art. Arch. Esp.Urol.2011; 64(1): 18–31.
4.
WitjesJ.A., RedortaJ.P., JacqminD.. Hexaminolevulinate-Guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and reccomendations.European Urology2010; 57: 607–614.
5.
KriegmarM., BaumgartnerR., KnuchelR., SteppH., HofstadterF., HofstetterA.Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence.J Urol1996 Jan; 155(1): 105–9.
6.
StenzlA.S., PoesslerW.R., FradetY.F.. Hexvix fluorescence cystoscopy improves detection and resection of papillary bladder cancer and reduces early recurrence: a multicentre, prospective, randomized study. 24th Annual European Association of Urology Congress; March 17–21; 2009.
7.
SchmidbauerJ., WitjesF., SchmellerN., DonatR., SusaniM., MarbergerM.Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy.J Urol2004; 171: 135–8.
8.
GrossmanH.B., GomellaL., FradetY.. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer.J Urol2007; 178: 62–7.
9.
FradetY., GrossmanH.B., GomellaL.. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study.J Urol2007; 178: 68–73.
10.
JochamD., WitjesF., WagnerS.. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study.J Urol2005; 174: 862–6.
11.
HerrK.S., DonatS.M.Quality control in transurethral resection of bladder tumours.BJU Int.2008; 102: 1242–46.
12.
MiladiM., PeyromaureM., ZerbibM.The value of a second transurethral resection in evaluating patients with bladder tumours.Eur Urol.2003; 43: 241–245.
13.
DwivediUdai S; KumarAbhay; DasSuren K; TrivediSameer; KumarMohan; SunderShyam; Singh PratapB.Relook TURBT in superficial bladder cancer: its importance and its correlation with the tumor ploidy.Urologic Oncology.2009; 27(5): 514–9.
14.
DivrikT., YildirimU., ErogluA.S., ZorluF., OzenH.Is a second transurethral resection necessary for newly diagnosed pT1 bladder cancer?J Urol.2006; 175: 1258–61.
15.
CinaS.J., EpsteinJ.I., EndrizziJ.M.. Correlation of cysto-scopic impression with histologic diagnosis of biopsy specimens of the bladder.Hum Pathol2001 Jun; 32(6): 630–7.
16.
CrowP., StoneN., KendallC.A., PersadR.A., WrightM P.Optical diagnosticsin urology: current applications and future prospects.BJU Int2003; 92: 400–7.
17.
IsfossB.L.. The sensitivity of fluorescent-light cystoscopy for the detection of carcinoma in situ (CIS) of the bladder: a meta-analysis with comments on gold standard.BJU Int.2011 Dec; 108(11): 1703–7.
18.
GeavleteB., MultescuR., GeorgescuD.. Treatment changes and long-term recurrence rates after hexaminolev-ulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?BJU Int.2012; 109(4): 549–56.
19.
LernerS.P., LiuH., WuM.F., ThomasY.K., WitjesJ.A.Fluorescence and white light cystoscopy for detection of carcinoma in situ of the bladder.Urol Oncol.2011 Mar 9.
20.
DragoescuO., TomescuP., PanusA.. Photodynamic diagnosis of non-muscle invasive bladder cancer using hexaminolevulinic acid.Rom J Morphol Embryol.2011; 52(1): 123–7.
21.
StenzlA., BurgerM., FradetY.. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with non muscle invasive bladder cancer.J Urol.2010 Nov; 184(5): 1907–13.
22.
DenzingerS., BurgerM., WalterB.. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study.Urology2007; 69: 675–9.
23.
FilbeckT., PichlmeierU., KnuechelR.. Clinically relevant improvement of recurrence-free survival with 5-aminolevu-linic acid induced fluorescence diagnosis in patients with superficial bladder tumours.J Urol2002; 168: 67–71.
24.
BabjukM., SoukupV., PetrikR.. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer.BJU Int2005; 96: 798–802.
25.
Danil'chenkoD.I., RiedlC.R., SachsM.D.. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study.J Urol2005; 174: 2129–33.
26.
HermannG.G., MogensenK., CarlssonS.. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study.BJU Int.2011 Oct; 108(8 Pt 2): E297–303.
27.
GrossmanH.B., StenzlA., FradetY.. Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy.J Urol.2012 Jul; 188(1): 58–62.
28.
BabjukM., OosterlinckW., SylvesterR., KaasinenE., BohleA., Palou-RedortaJ.EUA guidelines on non-muscle-invasive urothelial carcinoma of the bladder.Eur Urol.2008; 54: 303–14.
29.
DenzingerS., WielandW.F., OttoW., FielbeckT., KnuechelR., BurgerM.Does photodynamic transurethral resection of bladder tumor improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study.BJU Int.2008; 101: 566–569.
30.
JochamD., SteppH., WaidelichR.Photodynamic diagnosis in urology: state-of-the-art.Eur Urol2008; 53: 1138–50.
31.
CaubergE., de BruinD., FaberD., van LeeuwenT., de la RosetteJ., de ReijkeT.A new generation of optical diagnostic for bladder cancer: technology, diagnostic accuracy, and future applications.Eur Urol2009; 56: 287–297.
32.
RayE.R., ChattertonK., KhanM.S.. Hexaminolevulinate fluorescence cystoscopy in patients treated with intravesical bacille Calmette-Guerin.BJU Int.2010 Mar; 105(6): 789–94.
33.
BabjukM., OosterlinckW., SylvesterR., KaasinenE., BohleA., Palou-RedortaJ.EUA guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update.Eur Urol2011; 59.
34.
MalmstromP.U., GrabeM., HaugE.S.. Role of hexam-inolevulinate-guided fluorescence cystoscopy in bladder cancer: critical analysis of the latest data and European guidance.Scand J Urol Nephrol.2011 Nov 16.
35.
KuznetsovK., LambertR., ReyJ.F.Narrow-band imaging: potential and limitations.Endoscopy2006; 38: 76–81.
36.
SongL.M., AdlerD.G., ConwayJ.D.. Narrow band imaging and multiband imaging.Gastrointest Endosc2008; 67: 581–9.
37.
BryanR.T., BillinghamL.J., WallaceD.M.Narrow-band imaging flexible cystoscopy in the detection of recurrent urothelial cancer of the bladder.BJU Int2007; 101: 702–6.
38.
HerrH.W., DonatS.M.A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences.BJU Int2008; 102: 1111–4.
39.
NaselliA., IntroiniC., BertolottoF., SpinaB., PuppoP.Narrow band imaging for detecting residual/recurrent cancerous tissue during second transurethral resection of newly diagnosed non-muscle-invasive high-grade bladder cancer.BJU Int.2010 Jan; 105(2): 208–11.
40.
CaubergE.C.C., KloenS., VisserM.. Narrow band imaging cystoscopy improves the detection of nonmuscle invasive bladder cancer.Urology2010; 76: 658–663.
41.
BryanR.T., ShahZ.H., CollinsS.I., WallaceD.M.Narrow-band imaging flexible cystoscopy: a new user's experience.J Endourol.2010 Aug; 24(8): 1339–43.
42.
CaubergE.C.C., MamoulakisC., de la RosetteJJMCH, de ReijkeT.M.Narrow band imaging-assisted transurethral resection for nonmuscle invasive bladder cancer significantly reduces residual tumour rate.World J Urol2011.
CaubergE., de la RosetteJ., de BruinD., FaberD.J.. A new generation of optical diagnostics for bladder cancer: technology, diagnostic accuracy, and future applications.Eur Urol2009; 56: 287–297.
45.
LernerS., GohA., TresserN., ShenS.Optical coherence tomography as an adjunct to whire light cystoscopy for intravesical real-time imaging and staging of bladdder cancer.Urology2008; 72: 133–137.
46.
ManyakM.J., GladkovaN.D., MakariJ.H.. Evaluation of superficial bladder transitional-cell carcinoma by optical coherence tomography.J Endourol2005; 19: 570–4.
47.
SchmidbauerJ., RemziM., KlatteT.. Fluorescence cystoscopy with highresolution optical coherence tomography imaging as an adjunct reduces false-positive findings in the diagnosis of urothelial carcinoma of the bladder.Eur Urol2009; 56: 914–919.
48.
KarabacakO.R., CakmakciE., OzturkU., DemirelF.. Virtual cystoscopy: the evaluation of bladder lesions with computed tomographic virtual cystoscopy.Can Urol Assoc J2011; 5(1): 34–7.
49.
KivrakA.S., KiresiD., EmlikD., OdevK., KilincM.Comparison of CT virtual cystoscopy of the contrast material-filled bladder with conventional cystoscopy in the diagnosis of bladder tumours.Clinical Radiology2009; 64: 30–37.
